Literature DB >> 18668438

Peptide transporters and their roles in physiological processes and drug disposition.

I Rubio-Aliaga1, H Daniel.   

Abstract

1. The peptide transporters belong to the peptide transporter (PTR) family and serve as integral membrane proteins for the cellular uptake of di- and tripeptides in the organism. By their ability also to transport peptidomimetics and other substrates with therapeutic activities or precursors of pharmacologically active agents, they are of considerable importance in pharmacology. 2. PEPT1 is the low-affinity, high-capacity transporter and is mainly expressed in the small intestine, whereas PEPT2 is the high-affinity, low-capacity transporter and has a broader distribution in the organism. 3. Targeted mouse models have revealed PEPT2 to be the dominant transporter for the reabsorption of di- and tripeptides and its pharmacological substrates in the organism, and for the removal of these substrates from the cerebrospinal fluid. Moreover, the peptide transporters undergo physiological and pharmacological regulation and, of great interest, are present in disease states where PEPT1 exhibits ectopic expression in colonic inflammation. 4. The paper reviews the structural characteristics of the peptide transporters, the structural requirements for substrates, the distribution of the peptide transporters in the organism, and finally their regulation in the organism in healthy and pathological situations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18668438     DOI: 10.1080/00498250701875254

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  69 in total

1.  In Silico Absorption Analysis of Valacyclovir in Wildtype and Pept1 Knockout Mice Following Oral Dose Escalation.

Authors:  Bei Yang; David E Smith
Journal:  Pharm Res       Date:  2017-08-02       Impact factor: 4.200

2.  Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1.

Authors:  Larryn W Peterson; Monica Sala-Rabanal; Ivan S Krylov; Michaela Serpi; Boris A Kashemirov; Charles E McKenna
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

Review 3.  Bioavailability through PepT1: the role of computer modelling in intelligent drug design.

Authors:  David W Foley; Jeyaganesh Rajamanickam; Patrick D Bailey; David Meredith
Journal:  Curr Comput Aided Drug Des       Date:  2010-03       Impact factor: 1.606

4.  In vivo inhibition of trans-plasma membrane electron transport by antiviral drugs in grapevine.

Authors:  A Panattoni; E Rinaldelli; E Triolo; A Luvisi
Journal:  J Membr Biol       Date:  2013-06-18       Impact factor: 1.843

5.  THE EVALUATION OF PEPTIDE/HISTIDINE TRANSPORTER 1 (PHT1) FUNCTION: UPTAKE KINETICS UTILIZING A COS-7 STABLY TRANSFECTED CELL LINE.

Authors:  David J Lindley; Stephen M Carl; Stephanie A Mowery; Gregory T Knipp
Journal:  Rev Mex Cienc Farm       Date:  2011-10

6.  In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2013-11       Impact factor: 4.200

7.  The gut as a sensory organ.

Authors:  John B Furness; Leni R Rivera; Hyun-Jung Cho; David M Bravo; Brid Callaghan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-24       Impact factor: 46.802

8.  Expression and regulation of proton-coupled oligopeptide transporters in colonic tissue and immune cells of mice.

Authors:  Yuqing Wang; Yongjun Hu; Ping Li; Yayun Weng; Nobuhiko Kamada; Huidi Jiang; David E Smith
Journal:  Biochem Pharmacol       Date:  2018-01-03       Impact factor: 5.858

9.  Impact of intestinal PepT1 on the kinetics and dynamics of N-formyl-methionyl-leucyl-phenylalanine, a bacterially-produced chemotactic peptide.

Authors:  Shu-Pei Wu; David E Smith
Journal:  Mol Pharm       Date:  2013-01-07       Impact factor: 4.939

10.  Relevance of PepT1 in the intestinal permeability and oral absorption of cefadroxil.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.